CHRSHealthcare · BiotechnologyThe 7 Wall Street analysts covering Coherus Oncology, Inc. hold a median 12-month price target of $7 — +483.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 15 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Coherus Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (70): Analysts have, on balance, been raising their forecasts.
Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CHRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +483.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $12 → $10 |
| 11 May 2026 | Guggenheim | Initiates | Buy | — |
| 22 Jan 2026 | Oppenheimer | Initiates | Outperform | — |
| 4 Sept 2025 | Maxim Group | Upgrade | Buy | — |
| 29 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Apr 2025 | UBS | Maintains | Neutral | — |
| 11 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | Baird | Maintains | Outperform | — |
| 4 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | Baird | Maintains | Outperform | — |
| 7 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | UBS | Downgrade | Neutral | — |
| 5 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 July 2024 | Baird | Maintains | Outperform | — |
| 24 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | Truist Securities | Maintains | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CHRS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 68% of US stocks
Cheaper than 36% of US stocks
Cheaper than 35% of US stocks
Cheaper than 67% of US stocks
Higher than 83% of US stocks
Higher than 72% of US stocks
Higher than 83% of US stocks
Higher than 10% of US stocks
Higher than 1% of US stocks
Higher than 7% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Coherus Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Coherus Oncology, Inc. (CHRS) held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The transcript covers the company's second-quarter 2026 earnings discussion.
Why it matters — CHRS watchers would care because the Q2 2026 earnings call transcript provides direct insight into the company's most recent financial results and management commentary.
In its Q2 earnings call, Coherus Oncology reported continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise. The company also stated it is approaching several clinical data disclosures in the second half of 2026.
Why it matters — CHRS watchers would care because the upcoming clinical data readouts and reduced cost base could shape the company's near-term outlook and pipeline progress.
Coherus Oncology (CHRS) reported a second-quarter loss of $0.19 per share, missing the Zacks Consensus Estimate of $0.08. The loss narrowed compared with the $0.34 per share loss reported a year ago.
Why it matters — The quarterly result came in below analyst expectations, a relevant update for CHRS watchers assessing the company's recent earnings performance.
Coherus Oncology reported second quarter 2026 financial results, with LOQTORZI net revenue of $13.6 million, up 15% over the first quarter, and provided a business update noting clinical data maturing across programs with emerging evidence of tagmokitug activity in head and neck cancer. The company projected public disclosure of sufficiently mature data sets in October and scheduled a conference call for 5:00 p.m. Eastern Daylight Time.
Why it matters — CHRS watchers would care because the report highlights LOQTORZI revenue growth and signals an upcoming October disclosure of maturing clinical data for tagmokitug in head and neck cancer.
The 7 Wall Street analysts covering Coherus Oncology, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Coherus Oncology, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coherus Oncology, Inc. 53 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Coherus Oncology, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (70 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +483.3% from the last close, and Ticker Nerd's factor model ranks Coherus Oncology, Inc. 53 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Coherus Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
Coherus Oncology, Inc. returned +17.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Coherus Biosciences Inc. is a commercial-stage biopharmaceutical company focused on oncology therapeutics.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript". Coherus Oncology, Inc. (CHRS) held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The transcript covers the company's second-quarter 2026 earnings discussion.
Coherus Biosciences Inc. is a commercial-stage biopharmaceutical company focused on oncology therapeutics. It develops and commercializes innovative treatments, including the FDA-approved next-generation PD-1 inhibitor LOQTORZI (toripalimab-tpzi), approved for nasopharyngeal carcinoma and other cancers. The company also offers UDENYCA, a biosimilar referencing Neulasta for supportive care in oncology, and YUSIMRY, a Humira biosimilar. Its pipeline features mid-stage clinical candidates like CHS-114, a selective anti-CCR8 antibody targeting regulatory T cells in solid tumors such as head and neck, gastric, esophageal, and colorectal cancers, and casdozokitug, an IL-27 antagonist for liver, lung, and other advanced solid tumors. Coherus Biosciences Inc. emphasizes proprietary combinations and synergies with industry partners to advance immuno-oncology treatments. Founded in 2010 and headquartered in Redwood City, California, it operates in the biotechnology sector, generating revenue primarily from the United States through its diversified portfolio of approved products.
CEO Mr. Dennis M. Lanfear · 144 employees · United States · https://www.coherus.com